Technical Articles

B cell maturation antigen (BCMA), also known as TNFRSF17, is a member of the tumor necrosis factor receptor superfamily. It is mainly expressed on the surface of mature B lymphocytes and long-lived plasma cells, playing a key role in regulating B cell differentiation, survival, and antibody production.

As an important member of the RAS family, KRAS gene mutations have a high incidence and clinical relevance in human malignant tumors, and have become one of the core concerns in the field of cancer research.

At the forefront of medical research, the target BCMA (B cell maturation antigen) is gradually becoming a new focus of immunotherapy. Initially, BCMA was mainly focused on its potential in the treatment of multiple myeloma (MM), but recent research breakthroughs have given us new hope for its use in the treatment of autoimmune diseases.

In the fields of immunology and tumor therapy, IKZF1 (Ikaros) and IKZF3 (Aiolos) are emerging as research hotspots. They are not only critical transcription factors but also play important roles in regulating immune cell function and tumor cell proliferation.

In the realm of deubiquitinating enzymes (DUBs), the USP family undeniably takes center stage. With 56 members identified in humans, the USP family exhibits immense potential across oncology, immunomodulation, and beyond. Ulove Protein offers a comprehensive suite of USP proteins to empower your research endeavors!

The KRAS protein is an important target protein in cancer. The KRAS gene, whose full name is Kirsten rat sarcoma viral oncogene homolog, is translated as "Kirsten rat sarcoma virus oncogene homolog". The protein encoded by the KRAS gene is a small GTPase, which belongs to the RAS superfamily of proteins.

EphA2 is mainly restrictedly expressed in the proliferating epithelial cells of adults. However, an increasing number of studies have demonstrated that EphA2 is highly expressed in various cancers and is associated with poor prognosis, metastasis, and low survival rates. The active involvement of EphA2 in the tumor process, along with its relatively low expression in most normal adult tissues, makes this protein another potential therapeutic target for cancer.